Esperion officer Koenig proposes $169K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Esperion Therapeutics, Inc. (ESPR) officer and director Sheldon Koenig reported a proposed sale of 53,588 common shares, with an aggregate market value of $169,059.42 and an approximate sale date of June 17, 2026. He acquired the shares from the issuer through restricted stock vesting on June 16, 2026, as compensation. The notice states that the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. It lists 257,431,942 common shares outstanding. Koenig also reported a March 17, 2026 sale of 25,578 common shares for gross proceeds of $69,551.70. The notice was signed by Daniel Tucci, a duly authorized representative of Fidelity Brokerage Services LLC and attorney-in-fact for Koenig.
Key Figures
Key Terms
Restricted Stock Vesting financial
vested equity award distribution financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.